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Background: Porcine circovirus type 2 (PCV2) is considered to be an important emerging pathogen associated with a
number of different syndromes and diseases in pigs known as PCV2-associated diseases. It has been responsible for
significant mortality among pigs and remains a serious economic problem to the swine industry worldwide leading to
significant negative impacts on profitability of pork production.
Results: In this study we have demonstrated that PCV2 capsid (Cap) protein based virus-like particles (VLPs) were
efficiently produced in yeast S. cerevisiae and induced production of monoclonal antibodies (MAbs) reactive with
virus-infected cells. Moreover, PCV2 Cap VLPs served as a highly specific recombinant antigen for the development
of an indirect IgG PCV2 Cap VLP-based ELISA for the detection of virus-specific IgG antibodies in swine sera. Four
hundred-nine serum samples collected from pigs in Lithuania were tested for PCV2-specific IgG to determine the
sensitivity and specificity of the newly developed ELISA in parallel using a commercial SERELISA test as a gold
standard. From 409 tested serum samples, 297 samples were positive by both assays. Thirty-nine sera from 112 serum
samples were determined as negative by SERELISA but were found to be positive both in the newly developed indirect
IgG PCV2 Cap VLP-based ELISA and the PCR test.
Conclusions: We have demonstrated that S. cerevisiae expression system is an alternative to insect/baculovirus
expression system for production of homogenous in size and shape PCV2 Cap protein-based VLPs similar to native
virions. Yeast expression system tolerated native virus genes encoding PCV2 Cap protein variants as well as the
codon-optimized gene. Moreover, yeast-derived PCV2 Cap VLPs were capable to induce the generation of PCV2-specific
MAbs that did not show any cross-reactivity with PCV1-infected cells. The high sensitivity and specificity of the indirect
IgG PCV2 Cap VLP-based ELISA clearly suggested that this assay is potentially useful diagnostic tool for screening
PCV2–suspected samples.
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Circoviruses belong to the Circoviridae family and infect
a variety of animal and plant species. They are named
after their circular single-stranded DNA (ssDNA) gen-
ome and represent the smallest DNA viruses infecting
mammals. Porcine circovirus 2 (PCV2) is found all over
the world in the domestic pigs and the wild boars which
seldom display the clinical condition. PCV2 serological
prevalence in the wild boars is almost as high as in do-
mestic pigs [1]. PCV2 is considered to be an important
emerging pathogen associated with a number of different
syndromes and diseases in pigs known as PCV2-associated
diseases (PCVAD). Overall, PCVAD includes clinical syn-
dromes and diseases such as postweaning multisystemic
wasting syndrome (PMWS), porcine dermatitis and ne-
phropathy syndrome (PDNS), porcine reproductive disor-
ders, respiratory disease complex, granulomatous enteritis,
congenital tremor, necrotizing tracheitis and lymphadenitis
and exudative epidermitis [2-6]. PCV2 has been respon-
sible for significant mortality among pigs and remains a
serious economic problem to the swine industry world-
wide leading to significant negative impacts on profitability
of pork production [2]. The ubiquitous nature of the virus
and the retrospective evidence of this infection long before
disease appearance provided the reason for debate about
the real capabilities of this virus in its association with the
disease. How the virus causes disease is still not fully
understood. Infection with PCV2 in combination with still
unknown co-factors can cause immunopathological disor-
ders such as PMWS, or induce protective immunity. It
might be that PCV2-induced diseases are the result of
PCV2-caused immune disorder. It was demonstrated that
pigs with PMWS display a marked depletion of T- and
B-lymphocytes, and their lymphoid organs are infiltrated
by histiocytes and multinucleated giant cells and might
cause deficiency of total and neutralizing antibody re-
sponse [7,8]. The interaction of PCV2 with the innate im-
mune system have been mostly studied in vitro looking for
the effects of the virus on dendritic cells (DCs), macro-
phages and peripheral blood mononuclear cells [7]. It was
shown that PCV2 infection of plasmacytoid DCs impairs
the induction of interferon-α and tumor necrosis factor-α,
which silences responsiveness to pathogen-associated rec-
ognition signals by compromising immune defense devel-
opment against other pathogens. As a result this may lead
to a host susceptibility to secondary infections which
actually are responsible for developing of PCVAD [9].
PCV2 is a non-enveloped virus with circular single
stranded DNA molecule of approximately 1,767 bases
packed in icosahedral 12–23 nm diameter virion par-
ticle. Virus genome sequences with nucleotide diversity
cut-off of 3.5% were divided into four genotypic groups
[1]. The two major groups designated as PCV2a, PCV2b
are found worldwide and have been demonstrated to bevirulent enough to trigger PCVAD [1,10,11]. The two
more genotype types - PCV2c reported from Denmark
in the 1980s and PCV2d found in China are not distrib-
uted so widely [12,13].
The PCV2 genome contains two major open reading
frames (ORFs). The replicase (Rep and Rep’) proteins re-
sponsible for initiation of viral replication are encoded
by ORF1 located on the viral plus strand. A sole struc-
tural protein of the viral coat encoded by ORF2 on com-
plementary strand is the unique structural capsid (Cap)
protein [14]. Cap protein is the major immunogenic pro-
tein containing specific epitopes of PVC2 [15]. The Cap
protein reacts strongly with the serum of PCV2-infected
pigs and therefore, it is a major candidate antigen for
the development of serological diagnostic methods.
There were multiple attempts to produce recombinant
Cap protein in different expression systems including E.
coli, Lactococcus lactis, Pichia pastoris, baculovirus or
pseudorabies virus expression systems [15-21]. In most
cases the expression of ORF2 gene of PCV2 was achieved
by optimizing codon composition, removing N terminal
part of the protein rich of arginine residues or by adding
different tags useful for purification. These approaches
have been shown to be successful to yield truncated or
full length monomeric Cap protein. Expression of PCV2
Cap in insect cells resulted in recombinant protein self-
assembled into virus-like particles (VLPs) that were
structurally and antigenically indistinguishable from
regular PCV2 capsids [15]. Recombinant VLPs due to
their repetitive surface epitopes, the virus-like structure
and the capability to induce humoral and/or CTL re-
sponses are more suitable for the development of im-
munogenic vaccines and sensitive diagnostic tests as
compared to monomeric viral antigens [22]. At present,
few baculovirus-derived PCV2a subunit vaccines are
available [23]. PCV2 Cap VPLs produced in baculovirus
expression systems were shown to be a suitable antigen
for detection of PCV2 infection by the indirect IgG PCV2
ELISA [24,25]. However, the possibilities to employ cheaper
antigens for diagnostic purposes are considered mostly
by using monomerus PCV2 Cap protein [18,25-27].
In the current study we demonstrate that PCV2b-
derived Cap VLPs can be efficiently produced in yeast
Sacharomyces cerevisiae and are excellent antigens for
generation of monoclonal antibodies (MAbs) reactive
with virus-infected cells. Moreover, we demonstrate that
yeast-derived recombinant PCV2 Cap VLPs represent
a promising antigen for a highly sensitive and specific
immunoassay for serologic diagnosis of PCV2 infection.
Results
Production of PCV2 VLPs in yeast
PCV2-positive samples collected between 2009 and 2013
from domestic pigs from 9 regions of Lithuania were
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DNA with overlapping primers. DNA sequence alignment
of the 45 cloned and sequenced PCV2 genomes circulating
in Lithuania revealed six slightly different genome variants
(GenBank: KJ128269, KJ128270, KJ128271, KJ128272,
KJ128273, KJ128274). All six PCV2 genome variants
belonged to genotype PCV2b according to the previ-
ously proposed criteria [10,11].
Three open reading frame 2 (ORF2) variants amplified
by PCR from native PCV2 genomes: variant 622 (GenBank:
KJ128269), variant 521 (GenBank: KJ128273) and variant
113 (GenBank: KJ128274) as well as ORF2 of the most
representative PCV2-Cap gene variant 622 which was
codon-optimized by S. cerevisiae codon usage (GenBank:
KJ128275) were cloned into pFX7 expression vector [28]
and used for the expression in yeast S. cerevisiae.
The expression of four cloned genes was detected in
SDS-PAGE and confirmed by Western blot using pig
serum (Figure 1A,B). All recombinant PCV2-Cap pro-
teins were found in the soluble fraction of yeast cell lys-
ate which allowed their efficient purification (Figure 1A,
B, lanes 2, 4, 6, 8). All four variants of PCV2-Cap pro-
teins generated in yeast were purified by density gradient
centrifugation and examined using electron microscope
(EM). Despite the slight differences in expression levels
of PCV2-Cap gene variants, all four purified Cap pro-
teins were assembling into regular homogenous in size
VLPs about 17–22 nm in diameter similar to native
PCV2 virions (Figure 1C). PCV-Cap VLPs encoded by
the most representative PCV2-Cap gene variant 622
were used for generation of MAbs and development of
an indirect ELISA for detection of PCV2-specific IgG.
Generation and characterization of monoclonal
antibodies against PCV2b-Cap VLPs
To generate the MAbs, mice were immunized with re-
combinant PCV2 Cap 622 VLPs and tested for the pres-
ence of Cap-specific serum antibodies. Spleen cells of a
mouse showing the highest titer of Cap-specific anti-
bodies were used to generate hybridomas. After fusion,
all hybrid clones were screened for the reactivity with
PCV2 Cap VLPs and specific ones were subjected to
isotyping and recloning. After these procedures, three
stable hybridoma cell lines producing PCV2 Cap-specific
MAbs of IgG isotype were obtained. Two of them
(clones #14G10 and #7C4) produced MAbs of IgG2a
subtype and one clone (#24C7) of IgG1 subtype. The
specificity of all three MAbs was proven by ELISA using
all three variants of yeast-expressed Cap proteins: PCV2
Cap521 protein, PCV2 Cap113 protein, and PCV2 Cap622
protein. No reactivity of the MAbs with Hantaan (Fojnica)
and Tioman nucleocapsid proteins [29,30] used as a nega-
tive control was observed, which confirmed the specificity
of these MAbs to the PCV2 Cap protein (data not shown).Western blot analysis of MAb specificity using the
lysate of yeast expressing PCV2 Cap protein revealed
that only one MAb (clone #14G10) recognized SDS-
denaturated PCV2 Cap protein (data not shown). Mean-
while, the MAbs #7C4 and #24C7 did not react with
PCV2 Cap protein in Western blot thus indicating that
they are directed against conformational epitopes (data
not shown).
To evaluate the diagnostic potential of the generated
MAbs, their reactivity with PCV2-infected (virus strain
T-657) swine testicle cells (PT-1) and PCV1-infected
porcine kidney (PK) cells was tested by an indirect im-
munofluorescence assay (IFA) using commercially avail-
able slides (VMRD, Inc, Pullman, WA, USA). The MAbs
#7C4 and #14G10 were reactive with PCV2-infected
swine testicular cells but did not recognize PCV1-infected
PK cells thus confirming their specificity to PCV2 Cap
protein (Figure 2). Meanwhile, the MAb #24C7 was not
reactive in both IFA tests.
Development of an indirect ELISA for detection of PCV2
Cap-specific IgG
As a first step in the development of PCV2-Cap VLP-
based ELISA, checkerboard titrations were performed to
determine the optimal concentration of the Cap antigen
and the test serum. To optimize plate coating, the re-
combinant PCV2-Cap 622 protein was immobilized on
ELISA plates at five different concentrations: 2; 1; 0.5;
0.25; 0.125 μg/mL. The optimal antigen concentration
for plate coating as determined by a checkerboard titra-
tion was 0.5 μg/mL. To determine the optimal serum
sample dilution, serum samples identified by the com-
mercial SERELISA test (Synbiotics, Lyon, France) as high
positive, low positive and negative were diluted in serial
two fold dilutions ranging from 1:100 to 1:3200. The
OD450 values obtained in an indirect ELISA were plot-
ted against the dilutions (Figure 3). High OD readings
with positive control serum and low background signals
with negative sera were obtained at serum dilution 1:800.
The absorbance values declined at serum dilution 1:1600.
As the commercial SERELISA test uses serum dilution
1:1000 and the differences between OD values at serum
dilutions 1:800 and 1:1000 were insignificant in our
newly developed ELISA, for convenience the appropriate
dilution (1:1000) was selected for the indirect IgG PCV2
Cap-based ELISA. Control antigen – yeast expressed
Hamster polyomavirus (HaPyV) VP1 protein VLPs [28]
was included in the test to determine the specificity of the
assay. The positive samples revealed significantly higher
OD values (0.9–2.5) with PCV2 Cap protein as compared
to the control HaPyV-VP1 antigen (0.05–0.1) (Figure 4,
Dotted lines).
The cut-off value was calculated as the mean OD450
value of 42 serum specimens negative by SERELISA plus
Figure 1 Analysis of recombinant PCV2 Cap protein-derived VLPs produced in yeast. (A) Coomassie blue-stained SDS-PAGE; (B) Western
blot with pig serum. (A,B): In lanes: 1 - whole crude lysate of yeast transformed with pFX7-PCV2Cap-521 plasmid, 2 - the soluble fraction of the
lysate of yeast transformed with pFX7-PCV2Cap-521 plasmid; 3 - whole crude lysate of yeast transformed with pFX7- pFX7-PCV2Cap-113 plasmid;
4 - the soluble fraction of the lysate of yeast transformed with pFX7-PCV2Cap-113 plasmid; 5 - whole crude lysate of yeast transformed with
pFX7-PCV2Cap-622 plasmid; 6 - the soluble fraction of the lysate of yeast transformed with pFX7-PCV2Cap-622 plasmid; 7 - whole crude lysate of
yeast transformed with pFX7-PCV2Cap-622S plasmid; 8 - the soluble fraction of the lysate of yeast transformed with pFX7-PCV2Cap-622S plasmid;
9 - whole crude lysate of yeast transformed with pFX7 plasmid, M- pre-stained protein weight marker (Thermo Fisher Scientific Baltics); 10 - Cap521
protein VLPs purified by density gradient centrifugation; 11 - Cap113 protein VLPs purified by density gradient centrifugation; 12 – Cap622 protein VLPs
purified by density gradient centrifugation; 13 - Cap622S protein VLPs (Cap622 protein VLPs generated using synthetic codon-optimized gene) purified
by density gradient centrifugation. (C): Electron microscopy pictures of VLPs formed by PCV2-Cap521, protein PCV2-Cap113, protein PCV2-Cap622 and
protein PCV2-Cap622S protein stained with 2% aqueous uranyl acetate solution and examined by Morgagni 268 electron microscope.
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gives 99% confidence. The mean OD450 value and SD
were 0.146 and 0.053, respectively. Therefore, the posi-
tive threshold determined for the newly developed indir-
ect IgG PCV2 Cap VLP-based ELISA was 0.3. A serum
sample was considered positive when its OD450 value
was greater than the positive threshold (OD450 > 0.3).Four hundred-nine serum samples were tested to
determine the sensitivity and specificity of the newly
developed ELISA. The sensitivity and specificity were
calculated for the indirect IgG PCV2-Cap VLP-based
ELISA using SERELISA test as a gold standard. All
serum samples were tested in parallel with a commercial
SERELISA kit. From 409 serum samples tested, 297
Figure 2 Indirect immunofluorescence staining of PCV2 infected swine testicle (PT-1) cells and PCV1-infected PK cells with MAbs #7C4,
#14G10 and #24C7. NEG - MAb #4 F11 directed against parainfluenza type 3 N protein [41].
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sensitivity of the new ELISA test was 100% (297/297).
One hundred-twelve serum samples negative by SERE-
LISA were tested to determine the specificity of the in-
direct IgG PCV2-Cap VLP-based ELISA. Seventy-three
sera were below and 39 serum samples were above theFigure 3 Titration curves of swine serum samples. Either positive or ne
newly developed indirect IgG PCV2 Cap VLP-based ELISA using recombinant
antigen (HaPyV-VP1) at a concentration of 2 μg/ml (dotted line). Sera were te
The results are expressed as the OD450 and correspond to the average of thecut-off by indirect IgG PCV2-Cap VLP-based ELISA
(Figure 4, Table 1). Indirect IgG PCV2-Cap VLP-based
ELISA identified these samples as positive (Figure 4,
samples labeled with opened circles), although in the
commercial SERELISA test these samples were found to
be negative. Discrepant serum samples were re-tested bygative for PCV2 antibodies swine serum samples were titrated by the
PCV2 Cap VLPs at a concentration of 0.5 μg/ml (solid lines) and control
sted in serial duplicate twofold dilutions ranging from 1:100 to 1:3200.
values obtained in at least two different analyses.
Figure 4 Optical density results of serum samples in the newly developed indirect IgG PCV2 Cap VLP-based ELISA. Four hundred and
nine serum samples previously characterized by the commercial SERELISA test were analyzed by the newly developed indirect PCV2-Cap VLP IgG
ELISA. The absorbance at 450 nm obtained for the serum samples are shown. The dotted line indicates the assay cut-off, which was established to be
0.3. for the indirect PCV2 Cap VLP IgG ELISA. Opened circles represent discrepant results, filled circles indicate matching results with commercial SERELISA
test. ID sera, serum sample number.
Nainys et al. BMC Biotechnology 2014, 14:100 Page 6 of 11
http://www.biomedcentral.com/1472-6750/14/100PCR. Overall, all samples of the suspected PCV2 cases
were PCV2 DNA positive. Thus, samples positive by the
newly developed indirect IgG PCV2-Cap VLP-based
ELISA were confirmed by PCR but missed by commer-
cial SERELISA IgG test. All serum samples were tested
in duplicate and the correlation coefficient (r-value) be-
tween two measurements was calculated. The r value
was shown to be 0.972, which indicates very high repro-
ducibility between tests.
These results indicate that the newly developed indir-
ect IgG PCV2-Cap VLP-based ELISA had higher sensi-
tivity as compared to the commercial SERELISA test,Table 1 Comparative evaluation of the indirect IgG PCV2
Cap VLP-based ELISA with commercial SERELISA kit for





Positive 297 39 336
Negative 0 73 73
Total 297 112
The values represent the numbers of sera tested.which failed to detect some PCV2-positive samples as
positives.
Discussion
Virus-like particles present viral antigens in a more
authentic conformation than monomeric structural pro-
teins. Therefore, recombinant VLPs are more preferable
for vaccine or diagnostic purposes [22]. VLPs mimic the
structure of authentic virus particles they are derived
from and are easily recognized by the immune system
and able to stimulate both B-cell and T-cell immune
responses. Multiple expression systems such as E. coli,
L. lactis, P. pastoris allowed generation of monomeric
PCV2 Cap protein but not VLPs [16-20]. Different mod-
ifications of the gene encoding PCV2 protein were also
necessary for generation of recombinant PCV2 Cap pro-
tein including removal of the N terminal part with nu-
clear localization signal and fusing it with different tags
or yeast signal peptide as well as the optimization of
codon usage according to the host [16-21]. Even for
the investigation of the structure of PCV2 Cap-derived
VLPs, both the full length and an N-terminally truncated
monomeric Cap protein was purified from E.coli and
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baculovirus/insect cell expression system supported PCV2-
Cap protein self-assembly into VLPs [14,15]. Yeast Saccha-
romyces cerevisiae might provide an alternative expression
system for PCV2 Cap protein production as there are
several reports which confirm that yeast can support VLP
auto-assembly of viral proteins [32-34]. In a Bucarey’s
study, the failure of PCV2 Cap protein production in S.
cerevisiae using native PCV2-Cap coding sequence was
reported [35]. It was demonstrated that only codon op-
timized gene allowed generation of PCV2 Cap VLPs in
yeast. Moreover, in Bucarey’s study generated VLPs were
not homogenous in size and shape [35]. This is opposite
to our results presented in the current study (Figure 1).
We demonstrate that PCV2b-Cap VLPs were efficiently
produced in yeast S.cerevisiae using native virus ORF2
versions of Cap-encoding genes as well as the codon-
optimized gene. We purified three slightly different PCV2
Cap proteins variants encoded by native Cap-encoding
sequences and confirmed that they all formed homogenous
in size and shape VLPs similar to native virions or VLPs
produced in baculovirus expression system [14].
Yeast-produced PCV2 Cap VLPs were highly immuno-
genic and induced PCV2-specific immune response in
mice. We generated three MAbs with different capabilities
to recognize both the recombinant PCV2 Cap protein and
virus-infected cells. The MAb #14G10 demonstrated ex-
clusive and very specific reactivity with linear PCV2 Cap
protein epitope in Western blot, ELISA and IFA implying
the localization of this epitope on the surface of VLPs.
The MAb #24C7 was non-reactive with virus-infected
cells and did not recognize SDS-denaturated PCV2 Cap
protein, which suggests that its epitope is accessible only
in native PCV2 Cap VLPs. The MAb #7C4 also recog-
nized conformational PCV2 epitope but it was accessible
on virus-infected cells as demonstrated in IFA (Figure 2).
All three MAbs were highly specific and did not show
any cross-reactivity with PCV1 Cap protein in all assays
despite a significant homology between PCV2 and PCV1
(a non-pathogenic virus) in terms of amino-acid sequences.
Therefore, the newly generated MAb #7C4 and especially
the MAb #14G10 could be used as highly specific reagents
for PCV2 detection by IFA or monoclonal antibody-based
blocking ELISA.
The Cap protein is a major candidate antigen for the
development of serologic diagnostic methods as it is the
major immunogenic protein containing specific epitopes
of PVC2 [15]. In the previous studies recombinant
PCV2 Cap protein expressed in either prokaryotes or
eukaryotes was used in an indirect ELISA as coating
antigen. It was shown that PCV2 Cap VLPs or Cap pro-
tein expressed in insect cells as well as Cap protein
expressed in E. coli showed high immunoreactivity with
serum antibodies [18,24-26]. The diagnostic sensitivity,specificity, and accuracy of ELISAs performed with
PCV2 Cap VLPs and PCV2 were similar (>90%) to IFA
[24]. However the sensitivity of ELISA’s developed using
E. coli-expressed recombinant proteins were lower. This
is likely because natural virus particles are perfect in
structure whereas recombinant E. coli-expressed pro-
teins are not always refolded completely. Sun and
colleagues developed protein-based ELISA for PCV2
specific diagnosis using E. coli-expressed antigenic do-
main of PCV2 Cap protein [36]. The developed assay
failed to detect some PCV2-positive serum samples
identified by IFA. The specificity was lower also in a
monoclonal antibody-based blocking ELISA developed
by Huang and colleagues [37]. Its sensitivity and specifi-
city were determined to be 98.8% and 88.5%, respect-
ively. Higher sensitivity was achieved in a quantitative
immunofluorescence assay (QIFA) using the recombin-
ant PCV2 nucleocapsid protein expressed in Vero cells
by a lentivirus system, but the specificity was lower
when compared to ELISA [38]. In the current study, the
newly developed indirect IgG PCV2-Cap VLP-based
ELISA proved to be a highly sensitive and specific tool
for the serologic diagnosis of PCV2 infection and was
even more sensitive than the commercial SERELISA test.
It might be that not only VLP structure of yeast-
expressed Cap protein influenced the higher sensitivity
of the newly developed indirect IgG PCV2-Cap VLP-
based ELISA. Based on the GenBank database and sev-
eral studies published in different countries a shift on
genotype prevalence from PCV2a to b have been ob-
served [1]. Our analysis of PCV2 genotype spread in
Lithuania pig farms in the samples collected between
2009 and 2013 confirmed that all isolated virus genomes
belonged to the PCV2b genotype. Most of commercial
diagnostic tests are based on PCV2a genotype-derived
Cap proteins. Our preliminary data showed that some
PCV2-negative serum samples identified by a commer-
cial SERELISA test were negative in an indirect IgG Cap
VLP-based ELISA when PCV2a genotype-derived Cap
VPLs were used but were positive when PCV2b genotype-
derived Cap VLPs were used as a coating antigen. How-
ever to prove the hypothesis more serological assays
should be performed.
Conclusions
Recombinant VLPs are more preferable for vaccine de-
velopment or diagnostic purposes as they present viral
antigens in a proper conformation. In this study we have
demonstrated that S.cerevisiae expression system is an
alternative to insect/baculovirus expression system for
production of homogenous in size and shape PCV2 Cap
protein-based VLPs similar to native virions. Yeast cul-
tures are easy to maintain, which makes them faster and
less expensive to use than other eukaryotic expression
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native virus genes encoding PCV2 Cap protein variants as
well as the codon-optimized gene. Yeast-derived PCV2
Cap VLPs were capable to induce the generation of PCV2-
specific MAbs that did not show any cross-reactivity with
PCV1-infected cells. Moreover, the employment of PCV2
Cap VLPs as an antigen in the indirect IgG PCV2 Cap
VLP-based ELISA demonstrated that this newly developed
PCV2 diagnostic test was more sensitive and specific than
the commercial SERELISA test and is potentially useful
as a diagnostic assay in screening PCV2-suspected swine
samples.
Methods
Generation of yeast expression plasmids
All DNA manipulations were carried out according to
standard procedures [39]. Enzymes and kits for DNA
manipulations were purchased from UAB “Thermo Fisher
Scientific Baltics” Vilnius, Lithuania). Recombinants were
screened in E. coli DH5α cells.
PCV2 genome sequences were amplified using Phusion
High-Fidelity DNA Polymerase (Thermo Fisher Scientific
Baltics) from PCV2-positive samples of domestic pigs col-
lected between 2008 and 2013 from 9 regions of Lithuania,
sequenced with overlapping primers and aligned. PCV2
genome sequences with nucleotide variations were submit-
ted to GenBank (GenBank: KJ128269, KJ128270, KJ128271,
KJ128272, KJ128273, KJ128274). DNA sequences encoding
three different variants of PCV2 capsid protein sequences -
622 (GenBank: KJ128269), 521 (GenBank: KJ128273) and
113 (GenBank: KJ128274) - were PCR amplified from
DNA isolated from porcine serum or tissue samples col-
lected in Lithuanian pig farms. Collection of samples was
carried out in accordance with institutional guidelines and
permission of the national authorities (Permission No
0241). The PCV2 Cap-encoding DNA fragments were
amplified using Phusion High-Fidelity DNA Polymerase
(Thermo Fisher Scientific Baltics) to introduce BcuI
sites at the 5′ end 3′ ends of the PCR fragment using
primers CV-CP-Dir 5′CGACTAGTATGACGTATCCA
AGGAGGCGTTAC CG and CV-CP-rev 5′CGACTAG
TTAGGG GTTAAGTGGGGGGTCTTTAAG. Cloned
gene variants were sequenced. Additionally, the gene
encoding PCV2b-Cap protein 622 which appeared most
common in Lithuanian pigs samples was codon opti-
mized for expression in yeast (GenBank KJ128275). The
gene of PCV2b Cap 622 with yeast-optimized codons
(622S) was synthesized by GenScript. All four PCV2
Cap protein-encoding genes were cut with BcuI and
subcloned into the XbaI site of the yeast expression
vector pFX7 for target protein expression [28].
In addition, the gene encoding PCV1 Cap protein was
synthesized by GenScript and subcloned into the XbaI
site of the yeast expression vector pFX7.Detection of PCV2 virus DNA by PCR
Two-hundred microliters of porcine serum samples were
used to isolate viral genomic DNA with GeneJET™ Viral
RNA/DNA Purification Kit (Thermo Fisher Scientific
Baltics) according to the manufacturer’s recommendations.
Three pairs of primers (Rep-Bdir 5′ gccacctgggtgtggtaaaag
caaatg and PCV2-Xdir 5′tctagatgataactttgtaacaaaggc; Rep-
Bdir 5′ gccacctgggtgtggtaaaagcaaatg and PCV-cap-Csq 5′
ccgtgtaaccatgtatgtacaattcag; Rep-Brev 5′gtggccccacaat
gacgtgtacattag and PCV2-revsq cggtaacgcctccttggatac
gtc) were used to amplify PCV2 viral DNA fragments
from isolated DNA.
Yeast strains, growth media and cultivation conditions
The constructed plasmids pFX7-PCV2Cap-521, pFX7-
PCV2Cap-113, pFX7-PCV2Cap-622, pFX7-PCV2Cap-622S
and pFX7 were used for the transformation of S. cerevisiae
strain AH22-214 (a, leu2-3,112, his4-519). Yeast transfor-
mants harboring plasmids with PCV2-cap encoding genes
were grown in YEPD medium (yeast extract 1%, peptone
2%, and glucose 2%) supplemented with 5 mM formal-
dehyde overnight at 30°C and recombinant protein ex-
pression was induced after transferring yeast cells into
induction medium YEPG (yeast extract 1%, peptone 2%,
and galactose 3%) supplemented with 5 mM formalde-
hyde and culturing for additional 18 h. Yeast biomass
harboring recombinant proteins was harvested by cen-
trifugation and was stored at −20°C until use. Yeast
transformed with vector pFX7 without any insert was
used as a negative control.
SDS-PAGE and western blotting
Proteins were analyzed by electrophoresis on 12% sodium
dodecylsulfate-polyacrylamide gels (SDS-PAGE) followed
by Coomassie brilliant blue staining. Briefly, 20–50 mg of
yeast cell pellets were collected by centrifugation, washed
with distillate water and suspended in 20–50 μL of DB
150 buffer (150 mM NaCl, 1 mM CaCl2, 0.001% Trition
X-100, 0.25 M L-Arginine 10% glycerol in 10 mM Tris/
HCl-buffer, pH 6.5). An equal volume of glass beads was
added and the cells were lysed by vortexing for 7 min with
cooling on ice for 1 min between each vortexing step. The
samples of whole yeast lysates, the supernatant obtained
after centrifugation of whole yeast lysate and the purified
proteins were analyzed by SDS-PAGE. For this purpose,
the samples were mixed with the SDS-PAGE sample buf-
fer (Thermo Fisher Scientific Baltics), boiled for 5 min, ap-
plied to a SDS-PAGE and run in SDS-Tris-glycine buffer.
Protein bands in SDS-PAGE were visualized by staining
with Coomassie brilliant blue (Sigma–Aldrich, St. Louis,
MO, USA) or electro-transferred to Immobilon P mem-
brane (Millipore, Bedford, MA, USA). The membranes
were blocked with 5% milk in TTBS (0.1% Tween 20,
0.1 M Tris, 0.3 M NaCl, pH 7.4) and incubated overnight
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(RT). Porcine serum and the MAbs were diluted 1: 600
and 1:1,000, respectively, in TBS with 0.1% Tween 20.
After incubation with the diluted antibodies, the mem-
branes were incubated for 2 hours with HRP-labeled anti-
mouse IgG conjugate (Bio-Rad, Hercules, CA, USA) diluted
1:5000 or rabbit anti-pig IgG (Fab’2) conjugate (LifeSpan
Biosciences, Seattle, USA) diluted 1:10000. The peroxidase-
mediated staining was performed by adding 4-chloro-1-
naphtol and H2O2 (Fluka, Buchs, Switzerland).
Purification and characterization of PCV2-Cap VLPs
After centrifugation of yeast lysate, the supernatant con-
taining PCV2-Cap proteins was collected and loaded onto
a 20–69% sucrose gradient. Subsequently, a centrifugation
at 100,000 × g (Beckman Optima LE-80 K Ultracentrifuge,
Brea, CA, USA) overnight at 4°C followed. Thereafter,
fractions of 3 mL were collected and samples were sub-
jected to SDS-PAGE followed by Coomassie brilliant blue
staining. Fractions showing a protein band with an appar-
ent molecular mass of approximately 27 kDa correspond-
ing to PCV2 Cap protein were pooled and diluted in
DB150 buffer. The mixture was subjected to the ultracen-
trifugation on CsCl gradient with densities from 1.23 to
1.46 g/mL overnight at 100,000 × g (Beckman). Collected
fractions were analyzed as described above. After pooling
of the Cap-containing fractions, recombinant PCV2-Cap
VLPs were diluted and precipitated by ultracentrifugation
for 4 h at 100,000 × g (Beckman). The pellets were dis-
solved in PBS and dialyzed against PBS overnight. The
dialyzed PCV2-Cap VLPs were stored in PBS in 50%
glycerol at −20°C until use.
The samples of purified recombinant PCV2-Cap pro-
teins were placed on 300-mesh carbon coated palladium
grids, negatively stained with 2% aqueous uranyl acetate
solution and examined by Morgagni 268 electron micro-
scope (FEI Inc., Hillsboro, OR, USA).
Immunization of mice and generation of monoclonal
antibodies
All procedures involving laboratory mice were performed
at the breeding colony of the Center for Innovative
Medicine (Vilnius, Lithuania) under controlled labora-
tory conditions in strict accordance with Lithuanian and
European legislation.
To generate MAbs against the recombinant PCV2-
Cap protein, three BALB/c mice were injected subcuta-
neously 3 times with 50 μg of recombinant PCV2-Cap
VLPs at 21-day intervals. For a primary immunization,
the antigen was emulsified in Complete Freund’s adju-
vant (Sigma-Aldrich Co), the subsequent immunizations
were performed with PCV2 Cap VLPs dissolved in PBS
without adjuvant. After the 3rd immunization, serum
specimens were collected to determine the titers ofspecific antibodies. Finally, the mouse with the highest
anti-PCV2-Cap titer was boosted with the same dose of
PCV2-Cap VLPs in PBS and sacrificed for hybridoma
development.
Hybridomas were generated essentially as described
previously [40]. Four days after the booster immunization,
spleen cells of the immunized mouse were fused with
mouse myeloma Sp2/0 cells using PEG 1500 as a fusion
agent (PEG/DMSO solution, HybriMax, Sigma-Aldrich
Co). Hybrid cells were selected in growth medium supple-
mented with hypoxanthine, aminopterin and thymidine
(50 ×HAT media supplement, Sigma-Aldrich Co). Viable
clones were screened by an indirect ELISA using 96-well
microtiter plates coated with PCV2-Cap VLPs. Positive
clones were stabilized by limiting dilution cloning on
macrophage feeder layer. Hybridoma cells were main-
tained in complete Dulbecco’s modified Eagle’s medium
(DMEM) containing 15% fetal calf serum (FCS, Biochrom,
Cambridge, UK) and antibiotics. Heavy chain types of
MAbs were determined by ELISA using Monoclonal
Antibody Isotyping Kit (ISO-2, Sigma-Aldrich Co).
Indirect immunofluorescence assay
Indirect immunofluorescence assay (IFA) was performed
using commercial IFA slides for detection of PCV2-
infected (virus strain T-657) swine testicle cells (PT-1)
and PCV1-infected PK cells using commercially available
slides (VMRD, Inc, Pullman, WA, USA) as recom-
mended by the manufacturer. Briefly, 50 μL of cell cul-
ture supernatant of hybridomas #14G10, #24C7 and
#7C4 was added to the slides in a dilution of 1:50 in PBS
with 1% BSA or undiluted. The negative control MAb
#4 F11 directed against parainfluenza type 3 N protein
[41] was used at the same dilution. Detection was done
by incubation with a fluorescein isothiocyanate (FITC)-
conjugated anti-mouse immunoglobulin (H + L) goat
IgG (DakoCytomation) diluted 1:20 in PBS. Cells were
counter-stained with Evans Blue and IFA slides were an-
alyzed using Olympus IX-70 fluorescence microscope
(Olympus, Tokyo, Japan) with 40× objective at an excita-
tion of 495 nm and Image-pro Plus Version 7.0.
Serum samples
The porcine sera used in the study consisted of a collec-
tion of 409 samples obtained from 4–7 month old pigs
from different regions in Lithuania. Samples were stored
at −70°C prior to testing.
Indirect ELISA
The specificity of mouse antisera, MAbs and swine sera
was tested by an indirect ELISA. For testing the mouse
antisera and the MAbs microtiter plates (Nunc MaxiSorp,
Roskilde, Denmark) were coated with the respective anti-
gens by adding 100 μL of the antigen solution (2 μg/mL)
Nainys et al. BMC Biotechnology 2014, 14:100 Page 10 of 11
http://www.biomedcentral.com/1472-6750/14/100in coating buffer (50 mM sodium carbonate, pH 9.5) and
incubation overnight at +4°C. The plates were blocked for
30 min at RT with 1% bovine serum albumin (BSA) in
PBS and then incubated with either undiluted hybridoma
supernatant or serially diluted MAbs for 1 h at RT.
For the indirect IgG PCV2-Cap VLP ELISA microtiter
plates (Nerbe plus, Winsen/Luhe, Germany) were coated
with 100 μL per well of recombinant PCV2 Cap VLPs
(variant 622, GenBank: AHN49776) diluted in coating
buffer to the concentration of 0.5 μg/mL and incubated
overnight at +4°C. This concentration was determined
by titration to reach optimal conditions for sensitivity
and specificity. Control antigen - hamster polyomavirus
(HaPyV) VP1 protein VLPs [28] was diluted to the con-
centration of 2 μg/mL. The coated plates were blocked
with 150 μL/well of Roti-block (Carl Roth, Karlsruhe,
Germany) for 1 h at room temperature. Plates were
rinsed three times with washing buffer (PBS containing
0.1% Tween-20). The optimal serum dilution was deter-
mined by checkerboard titration (1:100, 1:200, 1:400,
1:800, 1:1600, 1:3200) in serum diluent (PBS containing
1% BSA and 0.05% Tween-20).
After 1 h of incubation the plates were rinsed five
times with washing buffer (PBS containing 0.1% Tween-
20) and incubated for 1 h at RT with HRP-labeled anti-
mouse IgG (Bio-Rad, diluted 1:5000 in PBS-T) or rabbit
anti-pig IgG (Fab’2; LifeSpan Biosciences, Seattle, USA)
diluted 1:15 000 in PBS, containing 1% BSA and 0.05%
Tween-20. The plates were washed as described above.
Binding of specific antibodies was detected by the
addition of 100 μL/well of TMB ready-to-use substrate
(Sigma) or TMB substrate (Clinical Science Products,
Mansfield, USA). After 10 min of incubation the reaction
was stopped by adding 100 μL/well of 10% sulphuric acid
and the optical density (OD) was measured at 450 nm
(reference filter 620 nm) in a microtiter plate reader
(Tecan, Groedig, Austria).
Characterization of serum samples by the commercial test
Serum samples were assayed for the presence of anti-
PCV2 antibodies using a commercial SERELISA PCV2 Ab
Mono Blocking Kit (Synbiotics, Lyon, France) as recom-
mended by the manufacturer. This ELISA is an epitope-
blocking assay in which labeled MAb against PCV2 Cap
protein is blocked from binding to the PCV2-coated
microtiter plate if the serum sample contains antibody
against PCV2. The test was performed according to the
recommendations of the manufacturer. Data management
and calculations were performed using software provided
by the manufacturer. Any sample presenting a S/N ratio ≤
to 0.4 and a titer >350 is considered positive for the pres-
ence of PCV2 Cap –specific antibodies in pig serum. Any
sample presenting a S/N ratio >0.4 and the titer ≤350 is
considered as “low antibody in serum” or non-reactive.Abbreviations
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